Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1TCR/dnTGFBRII Engineered T Cells + Decitabine in Advanced Solid Tumors
NCT07389239Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Sep 2026
- Primary completion
- Dec 2031
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of GSK3845097 in ovarian cancer, solid tumor, sponsored by University of Chicago. Started Sep 2026; status: recruiting.
02
Drugs
GSK3845097
03
Conditions
ovarian cancersolid tumor
Beyond the preview
Go deeper on NCT07389239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389239.